[1] ROY I, PATEL A, KUMAR V, et al. Polysorbate degradation and particle formation in a high concentration mAb: formulation strategies to minimize effect of enzymatic polysorbate degradation [J].Eur J Pharm Sci, 2021, 110(9): 3313
[2] GLUCKLICH N, CARLE S, BUSKE J. Assessing the polysorbate degradation fingerprints and kinetics of lipases-how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditions [J].Eur J Pharm Sci, 2021, 166(1): 105980
[3] ZHANG SS, XIAO H, LI N. Degradation of polysorbate 20 by sialateo-acetylesterase in monoclonal antibody formulations [J].J Pharm Sci(published online), doi.org/10.1016/j.xphs.2021.09.001
[4] GRAF T, TOMLINSON A, YUK IH. Identification and characterization of polysorbate-degrading enzymes in a monoclonal antibody formulation [J].J Pharm Sci, doi.org/10.1016/j.xphs.2021.06.033
[5] TOON L, THOMAS V W, MARTJIN V. Tolerability of polysorbate 80 containing COVID-19 vaccines in confirmed PEG allergic patients [J].J Allerg Clin Immun, doi.org/10.1016/j.jaip.2021.09.039
[6] KIM AM, LEE YW, KIM SR, et al. COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI Urticaria/ Angioedema/ Anaphylaxis Working Group [J].Allergy Asthma Immunol Res, 2021, 13(4): 526
[7] WAN L, LEE P. CMC of polysorbates [J].J Pharm Sci, 1974, 63(1): 136
[8] MAHLER HC, SENNER F, MAEDER K, et al. Surface activity of a monoclonal antibody[J].J Pharm Sci, 2009, 98(12):4525
[9] LIU L, QI W, SCHWARZ DK, et al. The effects of excipients on protein aggregation during agitation: an interfacial shear rheology study[J].J Pharm Sci, 2013, 102(8):2460
[10] GARIDEL P, HOFFMANN C, BLUME A. A thermodynamic analysis of the binding interaction between polysorbate 20 and 80 with human serum albumins and immunoglobulins: a contribution to understand colloidal protein stabilisation[J].Biophys Chem, 2009, 143(1-2):70
[11] RENUKA, THIUMANGALATHU, SAMPATHKUMAR, et al. Silicone oil-and agitation-induced aggregation of a monoclonal antibody in aqueous solution[J].J Pharm Sci, 2009, 98(9):3167
[12] KHAN TA, MAHLER HC, KISHORE RSK. Key interactions of surfactants in therapeutic protein formulations: a review[J].Eur J Pharm Biopharm, 2015, 97:60
[13] KAMERZELLTJ, ESFANDIARY R, JOSHI SB, et al. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development[J].Adv Drug Deliv Rev, 2011, 63(13):1118
[14] BAM NB, CLELAND JL, YANG J, et al. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions[J].J Pharm, 1998, 87(12):1554
[15] LEE HJ, MCAULEY A, SCHILKE KF, et al. Molecular origins of surfactant-mediated stabilization of protein drugs[J].Adv Drug Deliv Rev, 2011, 63(13):1160
[16] BALSE YL, CHENNELL P, TOKHADZE N, et al. Physicochemical stability of monoclonal antibodies: areview [J].J Pharm Sci, 2020, 109(1):169
[17] WANG W, ROBERTS CJ. Protein aggregation-mechanisms, detection, and control [J].Int J Appl Pharm, 2018, 550(1-2):251
[18] MEYER BK, COLESS L. Compounding and Filling: Drug Substance to Drug Product [M]// Meyer BK. Therapeutic Protein Drug Products: Practical Approaches to Formulation in the Laboratory, Manufacturing, and the Clinic. Britain: Woodhead Publishing, 2012: 83
[19] ZAPADKA KL, BECHER FJ, GOMES D, et al. Factors affecting the physical stability (aggregation) of peptide therapeutics[J].Interface Focus, 2017, 7(6):20170030
[20] PDR STAFF. Physician’s Desk Reference for Nonprescription Drugs[M].63rd Edit. Toronto: Thomson Reuters, 2009
[21] CHAUDHURI R, CHENG Y, MIDDAUGH CR, et al. High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability [J].AAPS J, 2014, 16(1): 48
[22] ARAKAWA T, TSUMOTO K, KITA Y, et al. Biotechnology applications of amino acids in protein purification and formulations[J].Amin Acids, 2007, 33(4):587
[23] JIN WX, XING ZZH, SONG YL, et al. Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification [J].mAbs, 2019, 11(8): 1479
[24] WANG L, YANG X, WANG Q, et al. Effects of ionic strength and temperature on the aggregation and deposition of multi-walled carbon nanotubes [J].2017, 51(1):248
[25] CHANG L, SHEPHERD D, SUN J, et al. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?[J].J Pharm Sci, 2005, 94(7):1427
[26] BEE JS, RANDOLPH TW, CARPENTER JF, et al. Effects of surfaces and leachables on the stability of biopharmaceuticals[J].J Pharm Sci, 2011, 100(10):4158
[27] LIM JY, KIM NA, LIM DG, et al. Biophysical stability of hyFc fusion protein with regards to buffers and various excipients[J].Int J Biol Macromol, 2016, 86:622
[28] AGARKHED M, O’DELL C, HSIEH MC, et al. Effect of surfactants on mechanical, thermal, and photostability of a monoclonal antibody[J].AAPS Pharm Sci Tech, 2018, 19(1):79
[29] KAORI, FUNATSU, HIDEAKI, et al. Impact of ethylene oxide sterilization of polymer-based prefilled syringes on chemical degradation of a model therapeutic protein during storage[J].J Pharm Sci, 2019, 108(1):770
[30] LIU W, SWIFT R, TORRACA G, et al. Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes [J].Pda J Pharm Sci Technol, 2010, 64(1):11
[31] HUANG M, HORWITZ TS, ZWEIBEN C, et al. Impact of extractables/leachables from filters on stability of protein formulations[J].J Pharm Sci, 2011, 100(11):4617
[32] JEZEK J, DARTON NJ, DERHAM BK, et al. Biopharmaceutical formulations for pre-filled delivery devices[J].Expert Opin Drug Deliv, 2013, 10(6):811
[33] RATNASWAMY G, HAIR A, LI G, et al. A case study of nondelamination glass dissolution resulting in visible particles: implications for neutral ph formulations[J].J Pharm Sci, 2014, 103(4):1104
[34] YF M, CC H. Investigation on fouling mechanisms for recombinant human growth hormone sterile filtration [J].J Pharm Sci, 1998, 87(7):808
[35] KIESE S, PAPPENBERGER A, FRIESS W, et al. Shaken, not stirred: mechanical stress testing of an IgG1 antibody [J].J Pharm Sci, 2008, 97(10):4347
[36] DOBON J, KUMAR A, WILLIS L F, et al. Inducing protein aggregation by extensional flow[J].Proc Natl Acad Sci USA, 2017, 114(18):4673
[37] CARPENTER JF, CHANG BS, GARZON-RODRIGUEZ W, et al. Rational design of stable lyophilized protein formulations: theory and practice[J].Pharm Biol, 2002, 13:109
[38] NEJADNIK MR, RANDOLPH TW, VOLKIN DB, et al. Postproduction handling and administration of protein pharmaceuticals and potential instability issues [J].J Pharm Sci, 2018, 107(8):2013
[39] THAKKAR SV, KIM JH, SAMRA HS, et al. Local dynamics and their alteration by excipients modulate the global conformational stability of an IgG1 monoclonal antibody [J].J Pharm Sci, 2012, 101(12):4444
[40] RANDOLPH TW, SCHILTZ E, SEDERSTROME D, et al. Do not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation [J].J Pharm Sci, 2015, 104(2):602
[41] BORISOV OV, JUNYAN AJ, WANG YJ, et al. Toward understanding molecular heterogeneity of polysorbates by application of liquid chromatography-mass spectrometry with computer-aided data analysis[J].Anal Chem, 2011, 83(10):3934
[42] KRANZ W, WUCHNER K, CORRADINI E, et al. Factors influencing polysorbate’s sensitivity against enzymatic hydrolysis and oxidative degradation[J].J Pharm Sci, 2019, 108(6):2022
[43] KISHORE R, KIESE S, FISCHER S, et al. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics[J].Pharm Res, 2011, 28(5):1194
[44] LI Y, HEWITT D, LENTZ YK, et al. Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh-performance liquid chromatography-charged aerosol detection-mass spectrometry[J].Anal Chem, 2014, 86(10):5150
[45] KISHORER, PAPPENBERGER A, DAUPHIN IB, et al. Degradation of polysorbates 20 and 80: Studies on thermal autoxidation and hydrolysis[J].J Pharm Sci, 2011, 100(2):721
[46] HA E, WANG W, WANG YJ. Peroxide formation in polysorbate 80 and protein stability [J].J Pharm Sci, 2002, 91(10):2252
[47] XM L, WG L, EK C, V L, CC H. Site-specific tryptophan oxidation induced by autocatalytic reaction of polysorbate 20 in protein formulation [J].Pharm Res, 2011, 28(10):2543
[48] ZHANG L, YADAV S, DEMEULE B, et al. Degradation mechanisms of polysorbate 20 differentiated by (18)O-labeling and mass spectrometry [J].Pharm Res, 2017, 34(1):84
[49] MCSHAN A C, KEI P, JI JA, et al. Hydrolysis of polysorbate 20 and 80 by a range of carboxylesterhydrolases[J].Pda J Pharm Sci Technol, 2016, 70(4):332
[50] DIXIT N, SALAMAT MN, SALINAS PA, et al. Residual host cell protein promotes polysorbate 20 degradation in a sulfatase drug product leading to free fatty acid particles[J].J Pharm Sci, 2016, 105(5): 1657
[51] PRAJAPATI I, PETERS BH, LARSON NR, et al. Cis/trans isomerization of unsaturated fatty acids in polysorbate 80 during light exposure of a monoclonal antibody-containing formulation [J].J Pharm Sci, 2020, 109(1):603
[52] DONBROW M, AZAZ E, PILLERSDORF A. Autoxidation of polysorbates [J].J Pharm Sci, 1978, 67(12):1676
[53] COATES LV, PAHSLEY MM, TATTERSALL K. The stability of antibacterials in polyethylene glycol mixtures[J].J Pharm Pharmacol, 2011, 13(1):620
[54] JAMES KC, LEACH RH. A stability study of chloramphenicol in topical formulations[J].J Pharm Pharmacol, 2011, 22(8):607
[55] KNEPP VM, WHATLEY JL, MUCHNIK A, et al. Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliaryneurotrophic factor and recombinant human nerve growth factor [J].Pda J Pharm Sci Technol, 1996, 50(3):163
[56] SIMAT TJ, STEINHART H. Oxidation of free tryptophan and tryptophan residues in peptides and proteins [J].J Agric Food Chem, 1998, 46(2):490
[57] JUNYAN A J. Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization [J].J Pharm Sci, 2009, 98(12):485
[58] GRAZИ V, ABIAN O, MATEO C, et al. Novel bifunctional epoxy/thiol-reactive support to immobilize thiol containing proteins by the epoxy chemistry[J].Biomacromolecules, 2003, 4(6):1495
[59] LAGERGARD T, LUNDQVIST A, WISHING A. Formaldehyde treatment increases the immunogenicity and decreases the toxicity of Haemophilusducreyicytolethal distending toxin [J].Vaccine, 2007, 25(18):3606
[60] MOGHADDAM AE, GARTLANK H, KONG L, et al. Reactive carbonyls are a major Th2-inducing damage-associated molecular pattern generated by oxidativestress[J].J Immunol, 2011, 187(4):1626
[61] TOROSANTUCCI R, SCHONEICH C, JISKOOT W. Oxidation of therapeutic proteins and peptides: structural and biological consequences [J].Pharm Res, 2014, 31(3):541
[62] JIA Y, DOKURU DK, NOESTHEDEN M, et al. A quantitative kinetic study of polysorbate autoxidation: the role of unsaturated fatty acid ester substituents [J].Pharm Res, 2009, 26(10):2303
[63] GRABAREK AD, BOZIC U, ROUSEL J, et al. What makes polysorbate functional? impact of polysorbate 80 grade and quality on igg stability during mechanical stress [J].J Pharm Sci, 2020, 109(1):871
[64] SINGH S M, BANDI S, JONES D, et al. Effect of polysorbate 20 and polysorbate 80 on the higher order structure of a monoclonal antibody and its fab and fc fragments probed using 2d NMR[J].J Pharm Sci, 2017, 106(12):3486
[65] YANG SH, LIU JJ, CHEN YQ. Reversal effect of Tween-20 on multidrug resistance in tumor cells in vitro [J].Biomed Pharmacother, 2012, 66(3):187
[66] HALL T, SANDEFUR SL, FRYE CC, et al. Polysorbates 20 and 80 degradation by group xv lysosomal phospholipase a2 isomer x1 in monoclonal antibody formulations[J].Eur J Pharm Sci, 2016, 105(5):1633
[67] MARTOS A, KOCH W, JISKOOT W, et al. Trends on analytical characterization of polysorbates and their degradation products in biopharmaceutical formulations[J].J Pharm, 2017, 106(7): 1722
[68] LABREN ZSR. Ester hydrolysis of polysorbate 80 in mab drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mab formulations[J].J Pharm Sci, 2014, 103(8):2268
[69] BATES TR, NIGHTINGALE CH, DIXON E. Kinetics of hydrolysis of polyoxyethylene (20) sorbitan fatty acid ester surfactants [J].J Pharm. Pharm Sci, 1973, 25(6):470
[70] LIPPOID S, KOSHARI SHS, KOPF R, et al. Impact of mono-and poly-ester fractions on polysorbate quantitation using mixed-mode HPLC-CAD/ELSD and the fluorescence micelle assay [J].J Pharm Biomed Anal, 2017, 132(2017):24
[71] SAVJANI N, BABCOCK E, KHOR HK, et al. Use of ferric thiocyanatederivatization for quantification of polysorbate 80 in high concentration protein formulations [J].Talanta, 2014, 130:542
[72] TOMLINSON A, DEMEULE B, LIN B, et al. Polysorbate 20 degradation in biopharmaceutical formulations: quantification of free fatty acids, characterization of particulates, and insights into the degradation mechanism[J].Mol Pharm, 2015, 12(11):3805
[73] SISKA CC, PIERINIC J, LAU HR, et al. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material[J].J Pharm Sci, 2015, 104(2):447
[74] MAGGIO, EDWARD T. Alkylsaccharides: circumventing oxidative damage to biotherapeutics caused by polyoxyethylene-based surfactants[J].Ther Deliv, 2013, 4(5):567
[75] BONAMICHI-SANTOS R, CASTELLS M. Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies[J].Clin Immunol, 2018, 54:375
[76] HOVGAARD L, SVEN F, MARCOVDW.Pharmaceutical Formulation Development of Peptides and Proteins [M].2nd Edition. Boca Raton: CRC Press, 2013
[77] BERGH M, MAGNUSSON K, NILSSON JLG, et al. Contact allergenic activity of Tween 80 before and after air exposure[J].Contact Derm, 2010, 37(1):9
[78] COOTRS EA, SEYBOLD H, MERK HF, et al. Polysorbate 80 in medical products and nonimmunologicanaphylactoid reactions[J].Ann Allerg Asthm Immunol, 2005, 95(6):593
[79] SHARMA B. Immunogenicity of therapeutic proteins. Part 1: impact of product handling[J].Biotechnol Adv, 2007, 25(3):310
[80] DEMEUL EB, MESSICK S, SHIRES J, et al. Characterization of particles in protein solutions: reaching the limits of current technologies[J].AAPS J, 2010, 12(4):708
[81] SAGGUM, LIU J, PATEL A. Identification of subvisible particles in biopharmaceutical formulations using Raman spectroscopy provides insight into polysorbate 20 degradation pathway[J].Pharm Res, 2015, 32(9):2877
[82] RAVURI KSK. Polysorbatedegradation and quality[M].NICHOLAS WW, HANNS CM. Challenges in Protein Product Development. Cham: Springer, 2018: 25
[83] JOHN FC, THEODORE WR, WIM J, et al. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality[J].J Pharm Sci, 2009, 98(4):1201
[84] SATUSH KS, NATALIYA A, MICHEL A, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics[J].J Pharm Sci, 2010, 99(8):3302
[85] GREGORITZA K, CAI SK, SIKETANC M.Metal-induced fatty acid particle formation resulting from hydrolytic polysorbate degradation [J].J Pharm Sci, doi.org/10.1016/j.xphs.2021.09.044
